nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—EPHX2—metabolic syndrome X	0.602	0.834	CbGaD
Sorafenib—HTR2C—metabolic syndrome X	0.12	0.166	CbGaD
Sorafenib—Regorafenib—EPHX2—metabolic syndrome X	0.00585	0.936	CrCbGaD
Sorafenib—PDGFRA—penis—metabolic syndrome X	0.00413	0.0423	CbGeAlD
Sorafenib—RET—autonomic nervous system—metabolic syndrome X	0.00408	0.0419	CbGeAlD
Sorafenib—CDKL3—cardiovascular system—metabolic syndrome X	0.0029	0.0298	CbGeAlD
Sorafenib—TIE1—endothelium—metabolic syndrome X	0.00268	0.0275	CbGeAlD
Sorafenib—CDKL3—adipose tissue—metabolic syndrome X	0.00256	0.0262	CbGeAlD
Sorafenib—TIE1—blood vessel—metabolic syndrome X	0.00247	0.0253	CbGeAlD
Sorafenib—FLT4—endothelium—metabolic syndrome X	0.00221	0.0227	CbGeAlD
Sorafenib—FLT4—blood vessel—metabolic syndrome X	0.00204	0.0209	CbGeAlD
Sorafenib—FLT1—artery—metabolic syndrome X	0.00204	0.0209	CbGeAlD
Sorafenib—Gastrointestinal symptom NOS—Metformin—metabolic syndrome X	0.00186	0.0643	CcSEcCtD
Sorafenib—Respiratory distress—Metformin—metabolic syndrome X	0.00173	0.0595	CcSEcCtD
Sorafenib—KDR—artery—metabolic syndrome X	0.00172	0.0177	CbGeAlD
Sorafenib—FLT1—endothelium—metabolic syndrome X	0.00172	0.0177	CbGeAlD
Sorafenib—FLT1—blood vessel—metabolic syndrome X	0.00159	0.0163	CbGeAlD
Sorafenib—KDR—endothelium—metabolic syndrome X	0.00146	0.0149	CbGeAlD
Sorafenib—Rhinorrhoea—Metformin—metabolic syndrome X	0.00135	0.0467	CcSEcCtD
Sorafenib—KDR—blood vessel—metabolic syndrome X	0.00134	0.0138	CbGeAlD
Sorafenib—KIT—endothelium—metabolic syndrome X	0.00129	0.0132	CbGeAlD
Sorafenib—MAPK11—adipose tissue—metabolic syndrome X	0.00125	0.0128	CbGeAlD
Sorafenib—CDK7—adipose tissue—metabolic syndrome X	0.00123	0.0126	CbGeAlD
Sorafenib—TAOK2—adipose tissue—metabolic syndrome X	0.00122	0.0125	CbGeAlD
Sorafenib—ZAK—cardiovascular system—metabolic syndrome X	0.00121	0.0124	CbGeAlD
Sorafenib—KIT—blood vessel—metabolic syndrome X	0.00119	0.0122	CbGeAlD
Sorafenib—HIPK3—cardiovascular system—metabolic syndrome X	0.00118	0.0121	CbGeAlD
Sorafenib—PDGFRB—blood vessel—metabolic syndrome X	0.00116	0.0119	CbGeAlD
Sorafenib—HIPK3—kidney—metabolic syndrome X	0.00115	0.0118	CbGeAlD
Sorafenib—TIE1—cardiovascular system—metabolic syndrome X	0.0011	0.0113	CbGeAlD
Sorafenib—ZAK—adipose tissue—metabolic syndrome X	0.00106	0.0109	CbGeAlD
Sorafenib—HIPK3—adipose tissue—metabolic syndrome X	0.00104	0.0107	CbGeAlD
Sorafenib—Neuropathy—Metformin—metabolic syndrome X	0.00103	0.0355	CcSEcCtD
Sorafenib—FLT3—cardiovascular system—metabolic syndrome X	0.001	0.0103	CbGeAlD
Sorafenib—TIE1—adipose tissue—metabolic syndrome X	0.000972	0.00997	CbGeAlD
Sorafenib—BRAF—adipose tissue—metabolic syndrome X	0.000932	0.00956	CbGeAlD
Sorafenib—FLT4—cardiovascular system—metabolic syndrome X	0.000911	0.00934	CbGeAlD
Sorafenib—UGT1A9—kidney—metabolic syndrome X	0.000904	0.00927	CbGeAlD
Sorafenib—EPHX2—adipose tissue—metabolic syndrome X	0.000891	0.00913	CbGeAlD
Sorafenib—CDK7—liver—metabolic syndrome X	0.000862	0.00884	CbGeAlD
Sorafenib—TAOK2—liver—metabolic syndrome X	0.000856	0.00877	CbGeAlD
Sorafenib—MKNK2—cardiovascular system—metabolic syndrome X	0.000824	0.00846	CbGeAlD
Sorafenib—MKNK1—cardiovascular system—metabolic syndrome X	0.000814	0.00835	CbGeAlD
Sorafenib—FLT4—adipose tissue—metabolic syndrome X	0.000803	0.00824	CbGeAlD
Sorafenib—Pain in extremity—Metformin—metabolic syndrome X	0.000796	0.0274	CcSEcCtD
Sorafenib—FGFR1—adipose tissue—metabolic syndrome X	0.000792	0.00813	CbGeAlD
Sorafenib—RET—kidney—metabolic syndrome X	0.000787	0.00807	CbGeAlD
Sorafenib—MAP3K7—adipose tissue—metabolic syndrome X	0.00075	0.00769	CbGeAlD
Sorafenib—ZAK—liver—metabolic syndrome X	0.000745	0.00764	CbGeAlD
Sorafenib—RALBP1—cardiovascular system—metabolic syndrome X	0.000745	0.00764	CbGeAlD
Sorafenib—Dehydration—Metformin—metabolic syndrome X	0.00074	0.0255	CcSEcCtD
Sorafenib—HIPK3—liver—metabolic syndrome X	0.000729	0.00748	CbGeAlD
Sorafenib—RALBP1—kidney—metabolic syndrome X	0.000728	0.00747	CbGeAlD
Sorafenib—MKNK2—adipose tissue—metabolic syndrome X	0.000727	0.00746	CbGeAlD
Sorafenib—Abdominal pain upper—Metformin—metabolic syndrome X	0.000727	0.0251	CcSEcCtD
Sorafenib—Breast disorder—Metformin—metabolic syndrome X	0.000719	0.0248	CcSEcCtD
Sorafenib—MKNK1—adipose tissue—metabolic syndrome X	0.000718	0.00736	CbGeAlD
Sorafenib—Nasopharyngitis—Metformin—metabolic syndrome X	0.000711	0.0245	CcSEcCtD
Sorafenib—FLT1—cardiovascular system—metabolic syndrome X	0.000708	0.00726	CbGeAlD
Sorafenib—RAF1—cardiovascular system—metabolic syndrome X	0.000704	0.00722	CbGeAlD
Sorafenib—FLT1—kidney—metabolic syndrome X	0.000693	0.00711	CbGeAlD
Sorafenib—RAF1—kidney—metabolic syndrome X	0.000689	0.00707	CbGeAlD
Sorafenib—TIE1—liver—metabolic syndrome X	0.000682	0.00699	CbGeAlD
Sorafenib—Pancreatitis—Metformin—metabolic syndrome X	0.000674	0.0232	CcSEcCtD
Sorafenib—STK10—cardiovascular system—metabolic syndrome X	0.00067	0.00688	CbGeAlD
Sorafenib—PDGFRA—cardiovascular system—metabolic syndrome X	0.000664	0.00681	CbGeAlD
Sorafenib—Abdominal discomfort—Metformin—metabolic syndrome X	0.000659	0.0227	CcSEcCtD
Sorafenib—RALBP1—adipose tissue—metabolic syndrome X	0.000657	0.00673	CbGeAlD
Sorafenib—STK10—kidney—metabolic syndrome X	0.000656	0.00673	CbGeAlD
Sorafenib—BRAF—liver—metabolic syndrome X	0.000654	0.0067	CbGeAlD
Sorafenib—Neutropenia—Metformin—metabolic syndrome X	0.000643	0.0222	CcSEcCtD
Sorafenib—EPHX2—liver—metabolic syndrome X	0.000625	0.00641	CbGeAlD
Sorafenib—FLT1—adipose tissue—metabolic syndrome X	0.000624	0.0064	CbGeAlD
Sorafenib—RAF1—adipose tissue—metabolic syndrome X	0.000621	0.00637	CbGeAlD
Sorafenib—FLT3—liver—metabolic syndrome X	0.00062	0.00636	CbGeAlD
Sorafenib—UGT1A1—kidney—metabolic syndrome X	0.000619	0.00635	CbGeAlD
Sorafenib—EPHB6—adipose tissue—metabolic syndrome X	0.000617	0.00633	CbGeAlD
Sorafenib—Infestation NOS—Metformin—metabolic syndrome X	0.000613	0.0211	CcSEcCtD
Sorafenib—Infestation—Metformin—metabolic syndrome X	0.000613	0.0211	CcSEcCtD
Sorafenib—Neuropathy peripheral—Metformin—metabolic syndrome X	0.000601	0.0207	CcSEcCtD
Sorafenib—KDR—cardiovascular system—metabolic syndrome X	0.000599	0.00614	CbGeAlD
Sorafenib—MAP2K5—cardiovascular system—metabolic syndrome X	0.000599	0.00614	CbGeAlD
Sorafenib—STK10—adipose tissue—metabolic syndrome X	0.000591	0.00606	CbGeAlD
Sorafenib—KDR—kidney—metabolic syndrome X	0.000586	0.00601	CbGeAlD
Sorafenib—PDGFRA—adipose tissue—metabolic syndrome X	0.000585	0.006	CbGeAlD
Sorafenib—CSF1R—cardiovascular system—metabolic syndrome X	0.000584	0.00599	CbGeAlD
Sorafenib—Hepatobiliary disease—Metformin—metabolic syndrome X	0.00058	0.02	CcSEcCtD
Sorafenib—UGT1A9—liver—metabolic syndrome X	0.000571	0.00586	CbGeAlD
Sorafenib—FLT4—liver—metabolic syndrome X	0.000563	0.00578	CbGeAlD
Sorafenib—FGFR1—liver—metabolic syndrome X	0.000556	0.0057	CbGeAlD
Sorafenib—Connective tissue disorder—Metformin—metabolic syndrome X	0.000541	0.0187	CcSEcCtD
Sorafenib—KIT—cardiovascular system—metabolic syndrome X	0.000531	0.00544	CbGeAlD
Sorafenib—MAP2K5—adipose tissue—metabolic syndrome X	0.000528	0.00541	CbGeAlD
Sorafenib—KDR—adipose tissue—metabolic syndrome X	0.000528	0.00541	CbGeAlD
Sorafenib—MAP3K7—liver—metabolic syndrome X	0.000526	0.0054	CbGeAlD
Sorafenib—KIT—kidney—metabolic syndrome X	0.000519	0.00532	CbGeAlD
Sorafenib—PDGFRB—cardiovascular system—metabolic syndrome X	0.000518	0.00531	CbGeAlD
Sorafenib—CSF1R—adipose tissue—metabolic syndrome X	0.000515	0.00528	CbGeAlD
Sorafenib—Flushing—Metformin—metabolic syndrome X	0.000511	0.0176	CcSEcCtD
Sorafenib—Cardiac disorder—Metformin—metabolic syndrome X	0.000511	0.0176	CcSEcCtD
Sorafenib—MKNK2—liver—metabolic syndrome X	0.00051	0.00523	CbGeAlD
Sorafenib—PDGFRB—kidney—metabolic syndrome X	0.000507	0.0052	CbGeAlD
Sorafenib—MKNK1—liver—metabolic syndrome X	0.000503	0.00516	CbGeAlD
Sorafenib—Angiopathy—Metformin—metabolic syndrome X	0.000499	0.0172	CcSEcCtD
Sorafenib—Immune system disorder—Metformin—metabolic syndrome X	0.000497	0.0171	CcSEcCtD
Sorafenib—Mediastinal disorder—Metformin—metabolic syndrome X	0.000496	0.0171	CcSEcCtD
Sorafenib—Malnutrition—Metformin—metabolic syndrome X	0.000479	0.0165	CcSEcCtD
Sorafenib—Erythema—Metformin—metabolic syndrome X	0.000479	0.0165	CcSEcCtD
Sorafenib—CYP3A7—liver—metabolic syndrome X	0.000475	0.00487	CbGeAlD
Sorafenib—Dysgeusia—Metformin—metabolic syndrome X	0.000469	0.0162	CcSEcCtD
Sorafenib—KIT—adipose tissue—metabolic syndrome X	0.000468	0.0048	CbGeAlD
Sorafenib—Muscle spasms—Metformin—metabolic syndrome X	0.000461	0.0159	CcSEcCtD
Sorafenib—RALBP1—liver—metabolic syndrome X	0.00046	0.00472	CbGeAlD
Sorafenib—PDGFRB—adipose tissue—metabolic syndrome X	0.000457	0.00469	CbGeAlD
Sorafenib—FLT1—liver—metabolic syndrome X	0.000438	0.00449	CbGeAlD
Sorafenib—RAF1—liver—metabolic syndrome X	0.000435	0.00447	CbGeAlD
Sorafenib—Syncope—Metformin—metabolic syndrome X	0.00043	0.0148	CcSEcCtD
Sorafenib—Loss of consciousness—Metformin—metabolic syndrome X	0.000421	0.0145	CcSEcCtD
Sorafenib—STK10—liver—metabolic syndrome X	0.000415	0.00425	CbGeAlD
Sorafenib—Hypertension—Metformin—metabolic syndrome X	0.000414	0.0143	CcSEcCtD
Sorafenib—PDGFRA—liver—metabolic syndrome X	0.00041	0.00421	CbGeAlD
Sorafenib—HTR2B—cardiovascular system—metabolic syndrome X	0.00041	0.00421	CbGeAlD
Sorafenib—Myalgia—Metformin—metabolic syndrome X	0.000408	0.0141	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Metformin—metabolic syndrome X	0.000405	0.014	CcSEcCtD
Sorafenib—CYP3A7-CYP3A51P—liver—metabolic syndrome X	0.000404	0.00414	CbGeAlD
Sorafenib—ABCC4—kidney—metabolic syndrome X	0.000404	0.00414	CbGeAlD
Sorafenib—Vismodegib—ALB—metabolic syndrome X	0.000402	0.0642	CrCbGaD
Sorafenib—UGT1A1—liver—metabolic syndrome X	0.000392	0.00402	CbGeAlD
Sorafenib—ABCC2—kidney—metabolic syndrome X	0.000391	0.00401	CbGeAlD
Sorafenib—Infection—Metformin—metabolic syndrome X	0.000388	0.0134	CcSEcCtD
Sorafenib—Shock—Metformin—metabolic syndrome X	0.000385	0.0133	CcSEcCtD
Sorafenib—Nervous system disorder—Metformin—metabolic syndrome X	0.000383	0.0132	CcSEcCtD
Sorafenib—Thrombocytopenia—Metformin—metabolic syndrome X	0.000383	0.0132	CcSEcCtD
Sorafenib—Skin disorder—Metformin—metabolic syndrome X	0.00038	0.0131	CcSEcCtD
Sorafenib—Anorexia—Metformin—metabolic syndrome X	0.000373	0.0129	CcSEcCtD
Sorafenib—KDR—liver—metabolic syndrome X	0.00037	0.0038	CbGeAlD
Sorafenib—MAP2K5—liver—metabolic syndrome X	0.00037	0.0038	CbGeAlD
Sorafenib—ABCC4—adipose tissue—metabolic syndrome X	0.000364	0.00373	CbGeAlD
Sorafenib—HTR2B—adipose tissue—metabolic syndrome X	0.000362	0.00371	CbGeAlD
Sorafenib—CSF1R—liver—metabolic syndrome X	0.000361	0.00371	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Metformin—metabolic syndrome X	0.000356	0.0123	CcSEcCtD
Sorafenib—Dyspnoea—Metformin—metabolic syndrome X	0.000349	0.012	CcSEcCtD
Sorafenib—Dyspepsia—Metformin—metabolic syndrome X	0.000344	0.0119	CcSEcCtD
Sorafenib—Decreased appetite—Metformin—metabolic syndrome X	0.00034	0.0117	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Metformin—metabolic syndrome X	0.000338	0.0116	CcSEcCtD
Sorafenib—Fatigue—Metformin—metabolic syndrome X	0.000337	0.0116	CcSEcCtD
Sorafenib—Constipation—Metformin—metabolic syndrome X	0.000334	0.0115	CcSEcCtD
Sorafenib—KIT—liver—metabolic syndrome X	0.000328	0.00336	CbGeAlD
Sorafenib—ABCB1—blood vessel—metabolic syndrome X	0.000322	0.0033	CbGeAlD
Sorafenib—PDGFRB—liver—metabolic syndrome X	0.00032	0.00329	CbGeAlD
Sorafenib—Gastrointestinal pain—Metformin—metabolic syndrome X	0.00032	0.011	CcSEcCtD
Sorafenib—Urticaria—Metformin—metabolic syndrome X	0.000311	0.0107	CcSEcCtD
Sorafenib—Abdominal pain—Metformin—metabolic syndrome X	0.000309	0.0107	CcSEcCtD
Sorafenib—CYP2C8—kidney—metabolic syndrome X	0.000293	0.00301	CbGeAlD
Sorafenib—Asthenia—Metformin—metabolic syndrome X	0.000281	0.00968	CcSEcCtD
Sorafenib—Pruritus—Metformin—metabolic syndrome X	0.000277	0.00954	CcSEcCtD
Sorafenib—CYP2B6—cardiovascular system—metabolic syndrome X	0.000269	0.00276	CbGeAlD
Sorafenib—Diarrhoea—Metformin—metabolic syndrome X	0.000268	0.00923	CcSEcCtD
Sorafenib—CYP2C9—cardiovascular system—metabolic syndrome X	0.000266	0.00273	CbGeAlD
Sorafenib—CYP3A5—kidney—metabolic syndrome X	0.000265	0.00271	CbGeAlD
Sorafenib—CYP2B6—kidney—metabolic syndrome X	0.000263	0.0027	CbGeAlD
Sorafenib—Dizziness—Metformin—metabolic syndrome X	0.000259	0.00892	CcSEcCtD
Sorafenib—ABCG2—adipose tissue—metabolic syndrome X	0.000257	0.00263	CbGeAlD
Sorafenib—ABCC4—liver—metabolic syndrome X	0.000255	0.00262	CbGeAlD
Sorafenib—Vomiting—Metformin—metabolic syndrome X	0.000249	0.00857	CcSEcCtD
Sorafenib—ABCC2—liver—metabolic syndrome X	0.000247	0.00253	CbGeAlD
Sorafenib—Rash—Metformin—metabolic syndrome X	0.000247	0.0085	CcSEcCtD
Sorafenib—Dermatitis—Metformin—metabolic syndrome X	0.000246	0.00849	CcSEcCtD
Sorafenib—Headache—Metformin—metabolic syndrome X	0.000245	0.00845	CcSEcCtD
Sorafenib—CYP3A5—adipose tissue—metabolic syndrome X	0.000238	0.00245	CbGeAlD
Sorafenib—Nausea—Metformin—metabolic syndrome X	0.000232	0.00801	CcSEcCtD
Sorafenib—CYP2C19—liver—metabolic syndrome X	0.000212	0.00218	CbGeAlD
Sorafenib—CYP3A4—kidney—metabolic syndrome X	0.000199	0.00204	CbGeAlD
Sorafenib—CYP2D6—kidney—metabolic syndrome X	0.000195	0.002	CbGeAlD
Sorafenib—CYP2C8—liver—metabolic syndrome X	0.000185	0.0019	CbGeAlD
Sorafenib—ABCG2—liver—metabolic syndrome X	0.00018	0.00185	CbGeAlD
Sorafenib—CYP1A2—liver—metabolic syndrome X	0.000173	0.00178	CbGeAlD
Sorafenib—CYP3A5—liver—metabolic syndrome X	0.000167	0.00171	CbGeAlD
Sorafenib—CYP2B6—liver—metabolic syndrome X	0.000166	0.0017	CbGeAlD
Sorafenib—CYP2C9—liver—metabolic syndrome X	0.000165	0.00169	CbGeAlD
Sorafenib—ABCB1—cardiovascular system—metabolic syndrome X	0.000144	0.00147	CbGeAlD
Sorafenib—ABCB1—kidney—metabolic syndrome X	0.000141	0.00144	CbGeAlD
Sorafenib—ABCB1—adipose tissue—metabolic syndrome X	0.000127	0.0013	CbGeAlD
Sorafenib—CYP3A4—liver—metabolic syndrome X	0.000125	0.00129	CbGeAlD
Sorafenib—CYP2D6—liver—metabolic syndrome X	0.000123	0.00127	CbGeAlD
Sorafenib—ABCB1—liver—metabolic syndrome X	8.88e-05	0.000911	CbGeAlD
Sorafenib—UGT1A9—Metabolism—PTGS2—metabolic syndrome X	3.93e-06	2.71e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TGFB1—metabolic syndrome X	3.92e-06	2.7e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCL2—metabolic syndrome X	3.92e-06	2.7e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NOS3—metabolic syndrome X	3.92e-06	2.7e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—SERPINE1—metabolic syndrome X	3.91e-06	2.7e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GGT1—metabolic syndrome X	3.87e-06	2.67e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GOT1—metabolic syndrome X	3.87e-06	2.67e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PLA2G6—metabolic syndrome X	3.86e-06	2.66e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IGF1—metabolic syndrome X	3.85e-06	2.66e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOA5—metabolic syndrome X	3.82e-06	2.64e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—ALB—metabolic syndrome X	3.81e-06	2.63e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—SCARB1—metabolic syndrome X	3.79e-06	2.62e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	3.78e-06	2.61e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—ALB—metabolic syndrome X	3.78e-06	2.6e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—APOB—metabolic syndrome X	3.77e-06	2.6e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ABCA1—metabolic syndrome X	3.77e-06	2.6e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—SLC2A4—metabolic syndrome X	3.77e-06	2.6e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PPARA—metabolic syndrome X	3.76e-06	2.59e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NOS3—metabolic syndrome X	3.74e-06	2.58e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—SLC2A4—metabolic syndrome X	3.73e-06	2.58e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ABCA1—metabolic syndrome X	3.73e-06	2.58e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—TGFB1—metabolic syndrome X	3.7e-06	2.55e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—metabolic syndrome X	3.69e-06	2.55e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—SREBF1—metabolic syndrome X	3.68e-06	2.54e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PPARA—metabolic syndrome X	3.67e-06	2.53e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PLA2G4A—metabolic syndrome X	3.67e-06	2.53e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—SERPINE1—metabolic syndrome X	3.66e-06	2.52e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GOT1—metabolic syndrome X	3.65e-06	2.52e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GGT1—metabolic syndrome X	3.65e-06	2.52e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—NOS3—metabolic syndrome X	3.64e-06	2.51e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AGT—metabolic syndrome X	3.64e-06	2.51e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—AKT1—metabolic syndrome X	3.62e-06	2.5e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GOT1—metabolic syndrome X	3.62e-06	2.5e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GGT1—metabolic syndrome X	3.62e-06	2.5e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—NOS3—metabolic syndrome X	3.61e-06	2.49e-05	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—AKT1—metabolic syndrome X	3.6e-06	2.49e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—LPL—metabolic syndrome X	3.6e-06	2.48e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—IL6—metabolic syndrome X	3.59e-06	2.48e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IRS1—metabolic syndrome X	3.59e-06	2.48e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GOT2—metabolic syndrome X	3.58e-06	2.47e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—HMGCR—metabolic syndrome X	3.58e-06	2.47e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—APOE—metabolic syndrome X	3.57e-06	2.46e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AGT—metabolic syndrome X	3.56e-06	2.45e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TRIB3—metabolic syndrome X	3.55e-06	2.45e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL6—metabolic syndrome X	3.54e-06	2.44e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL6—metabolic syndrome X	3.54e-06	2.44e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—APOA1—metabolic syndrome X	3.52e-06	2.43e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NOS3—metabolic syndrome X	3.49e-06	2.41e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—APOE—metabolic syndrome X	3.48e-06	2.4e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—APOA1—metabolic syndrome X	3.44e-06	2.38e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—INS—metabolic syndrome X	3.44e-06	2.37e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CD36—metabolic syndrome X	3.42e-06	2.36e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCL2—metabolic syndrome X	3.38e-06	2.33e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TGFB1—metabolic syndrome X	3.37e-06	2.32e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APOB—metabolic syndrome X	3.37e-06	2.32e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL6—metabolic syndrome X	3.36e-06	2.32e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL6—metabolic syndrome X	3.35e-06	2.31e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TGFB1—metabolic syndrome X	3.34e-06	2.3e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTGS2—metabolic syndrome X	3.33e-06	2.3e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IGF1—metabolic syndrome X	3.33e-06	2.29e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—AKT1—metabolic syndrome X	3.31e-06	2.29e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTGS2—metabolic syndrome X	3.3e-06	2.28e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—TGFB1—metabolic syndrome X	3.3e-06	2.28e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOB—metabolic syndrome X	3.29e-06	2.27e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PLA2G4A—metabolic syndrome X	3.27e-06	2.26e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—IL6—metabolic syndrome X	3.27e-06	2.26e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—AKT1—metabolic syndrome X	3.27e-06	2.25e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—AKT1—metabolic syndrome X	3.27e-06	2.25e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	3.23e-06	2.23e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—LPL—metabolic syndrome X	3.21e-06	2.22e-05	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—AKT1—metabolic syndrome X	3.2e-06	2.21e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PLA2G4A—metabolic syndrome X	3.2e-06	2.2e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ABCA1—metabolic syndrome X	3.19e-06	2.2e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—SLC2A4—metabolic syndrome X	3.19e-06	2.2e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NAMPT—metabolic syndrome X	3.19e-06	2.2e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARA—metabolic syndrome X	3.18e-06	2.19e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—LIPC—metabolic syndrome X	3.17e-06	2.18e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GCK—metabolic syndrome X	3.17e-06	2.18e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SERPINE1—metabolic syndrome X	3.16e-06	2.18e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—metabolic syndrome X	3.15e-06	2.17e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOC3—metabolic syndrome X	3.15e-06	2.17e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—LPL—metabolic syndrome X	3.14e-06	2.16e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PPARG—metabolic syndrome X	3.11e-06	2.14e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—metabolic syndrome X	3.1e-06	2.14e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—AKT1—metabolic syndrome X	3.1e-06	2.14e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOB—metabolic syndrome X	3.1e-06	2.14e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—metabolic syndrome X	3.1e-06	2.14e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—AKT1—metabolic syndrome X	3.09e-06	2.13e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GGT1—metabolic syndrome X	3.09e-06	2.13e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GOT1—metabolic syndrome X	3.09e-06	2.13e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AGT—metabolic syndrome X	3.08e-06	2.12e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOB—metabolic syndrome X	3.07e-06	2.12e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CETP—metabolic syndrome X	3.06e-06	2.11e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CD36—metabolic syndrome X	3.05e-06	2.11e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—INS—metabolic syndrome X	3.05e-06	2.1e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—metabolic syndrome X	3.04e-06	2.1e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—metabolic syndrome X	3.04e-06	2.1e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PPARG—metabolic syndrome X	3.04e-06	2.09e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—metabolic syndrome X	3.03e-06	2.09e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—metabolic syndrome X	3.02e-06	2.08e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—APOE—metabolic syndrome X	3.02e-06	2.08e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—AKT1—metabolic syndrome X	3.02e-06	2.08e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NOS3—metabolic syndrome X	3.02e-06	2.08e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PLA2G4A—metabolic syndrome X	3.01e-06	2.08e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PLA2G4A—metabolic syndrome X	2.99e-06	2.06e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—APOA1—metabolic syndrome X	2.98e-06	2.06e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CD36—metabolic syndrome X	2.98e-06	2.06e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—INS—metabolic syndrome X	2.98e-06	2.05e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—LPL—metabolic syndrome X	2.96e-06	2.04e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—metabolic syndrome X	2.95e-06	2.04e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—metabolic syndrome X	2.95e-06	2.03e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—LPL—metabolic syndrome X	2.93e-06	2.02e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SCARB1—metabolic syndrome X	2.93e-06	2.02e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AKT1—metabolic syndrome X	2.91e-06	2.01e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—metabolic syndrome X	2.88e-06	1.99e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—metabolic syndrome X	2.88e-06	1.98e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—AKT1—metabolic syndrome X	2.86e-06	1.97e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—AKT1—metabolic syndrome X	2.86e-06	1.97e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SREBF1—metabolic syndrome X	2.84e-06	1.96e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARA—metabolic syndrome X	2.84e-06	1.96e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CD36—metabolic syndrome X	2.81e-06	1.94e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—metabolic syndrome X	2.8e-06	1.93e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—metabolic syndrome X	2.79e-06	1.93e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—metabolic syndrome X	2.79e-06	1.92e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—metabolic syndrome X	2.79e-06	1.92e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CD36—metabolic syndrome X	2.78e-06	1.92e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARA—metabolic syndrome X	2.77e-06	1.91e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GOT2—metabolic syndrome X	2.76e-06	1.91e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HMGCR—metabolic syndrome X	2.76e-06	1.91e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AGT—metabolic syndrome X	2.75e-06	1.9e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—metabolic syndrome X	2.73e-06	1.88e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—metabolic syndrome X	2.72e-06	1.88e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—metabolic syndrome X	2.72e-06	1.87e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APOE—metabolic syndrome X	2.69e-06	1.86e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—metabolic syndrome X	2.69e-06	1.86e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AGT—metabolic syndrome X	2.68e-06	1.85e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NOS3—metabolic syndrome X	2.67e-06	1.84e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APOA1—metabolic syndrome X	2.66e-06	1.84e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOE—metabolic syndrome X	2.63e-06	1.81e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARG—metabolic syndrome X	2.63e-06	1.81e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOB—metabolic syndrome X	2.62e-06	1.81e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARA—metabolic syndrome X	2.61e-06	1.8e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NOS3—metabolic syndrome X	2.61e-06	1.8e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOA1—metabolic syndrome X	2.6e-06	1.79e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—metabolic syndrome X	2.59e-06	1.79e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARA—metabolic syndrome X	2.59e-06	1.79e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—metabolic syndrome X	2.58e-06	1.78e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—INS—metabolic syndrome X	2.58e-06	1.78e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—metabolic syndrome X	2.57e-06	1.77e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PLA2G4A—metabolic syndrome X	2.55e-06	1.76e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—metabolic syndrome X	2.54e-06	1.75e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—metabolic syndrome X	2.54e-06	1.75e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AGT—metabolic syndrome X	2.53e-06	1.74e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—metabolic syndrome X	2.52e-06	1.74e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AGT—metabolic syndrome X	2.51e-06	1.73e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—LPL—metabolic syndrome X	2.5e-06	1.73e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—metabolic syndrome X	2.49e-06	1.71e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—metabolic syndrome X	2.48e-06	1.71e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOE—metabolic syndrome X	2.48e-06	1.71e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—metabolic syndrome X	2.47e-06	1.7e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ABCA1—metabolic syndrome X	2.46e-06	1.7e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC2A4—metabolic syndrome X	2.46e-06	1.7e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOE—metabolic syndrome X	2.46e-06	1.69e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOA1—metabolic syndrome X	2.45e-06	1.69e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—metabolic syndrome X	2.44e-06	1.69e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOA1—metabolic syndrome X	2.43e-06	1.68e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—metabolic syndrome X	2.39e-06	1.65e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GGT1—metabolic syndrome X	2.39e-06	1.65e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GOT1—metabolic syndrome X	2.39e-06	1.65e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CD36—metabolic syndrome X	2.38e-06	1.64e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—metabolic syndrome X	2.36e-06	1.63e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARG—metabolic syndrome X	2.35e-06	1.62e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—metabolic syndrome X	2.35e-06	1.62e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—metabolic syndrome X	2.34e-06	1.62e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—metabolic syndrome X	2.32e-06	1.6e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—metabolic syndrome X	2.31e-06	1.59e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—INS—metabolic syndrome X	2.3e-06	1.59e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—metabolic syndrome X	2.29e-06	1.58e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARG—metabolic syndrome X	2.29e-06	1.58e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—metabolic syndrome X	2.29e-06	1.58e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—metabolic syndrome X	2.29e-06	1.58e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NOS3—metabolic syndrome X	2.26e-06	1.56e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—INS—metabolic syndrome X	2.25e-06	1.55e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARA—metabolic syndrome X	2.21e-06	1.53e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—metabolic syndrome X	2.17e-06	1.5e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—metabolic syndrome X	2.17e-06	1.5e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARG—metabolic syndrome X	2.16e-06	1.49e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AGT—metabolic syndrome X	2.14e-06	1.48e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARG—metabolic syndrome X	2.14e-06	1.48e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—INS—metabolic syndrome X	2.12e-06	1.46e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—metabolic syndrome X	2.11e-06	1.46e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—metabolic syndrome X	2.11e-06	1.46e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—metabolic syndrome X	2.11e-06	1.46e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOE—metabolic syndrome X	2.1e-06	1.45e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—INS—metabolic syndrome X	2.1e-06	1.45e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOA1—metabolic syndrome X	2.08e-06	1.43e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—metabolic syndrome X	2.07e-06	1.43e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—metabolic syndrome X	2.06e-06	1.42e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOB—metabolic syndrome X	2.02e-06	1.4e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NOS3—metabolic syndrome X	2.02e-06	1.39e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—metabolic syndrome X	2e-06	1.38e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—metabolic syndrome X	2e-06	1.38e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—metabolic syndrome X	1.99e-06	1.38e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—metabolic syndrome X	1.97e-06	1.36e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—metabolic syndrome X	1.97e-06	1.36e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NOS3—metabolic syndrome X	1.97e-06	1.36e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PLA2G4A—metabolic syndrome X	1.97e-06	1.36e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—metabolic syndrome X	1.95e-06	1.35e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—metabolic syndrome X	1.94e-06	1.34e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—LPL—metabolic syndrome X	1.93e-06	1.33e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—metabolic syndrome X	1.92e-06	1.33e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—metabolic syndrome X	1.86e-06	1.28e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NOS3—metabolic syndrome X	1.86e-06	1.28e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—metabolic syndrome X	1.85e-06	1.27e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NOS3—metabolic syndrome X	1.84e-06	1.27e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CD36—metabolic syndrome X	1.84e-06	1.27e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARG—metabolic syndrome X	1.83e-06	1.26e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—metabolic syndrome X	1.8e-06	1.24e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—metabolic syndrome X	1.8e-06	1.24e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—INS—metabolic syndrome X	1.79e-06	1.24e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—metabolic syndrome X	1.74e-06	1.2e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—metabolic syndrome X	1.72e-06	1.19e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARA—metabolic syndrome X	1.71e-06	1.18e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—metabolic syndrome X	1.7e-06	1.17e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—metabolic syndrome X	1.68e-06	1.16e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—metabolic syndrome X	1.68e-06	1.16e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—metabolic syndrome X	1.66e-06	1.15e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AGT—metabolic syndrome X	1.65e-06	1.14e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—metabolic syndrome X	1.64e-06	1.13e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOE—metabolic syndrome X	1.62e-06	1.12e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—metabolic syndrome X	1.61e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOA1—metabolic syndrome X	1.6e-06	1.1e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NOS3—metabolic syndrome X	1.57e-06	1.08e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—metabolic syndrome X	1.5e-06	1.04e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—metabolic syndrome X	1.44e-06	9.92e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARG—metabolic syndrome X	1.41e-06	9.73e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—metabolic syndrome X	1.39e-06	9.56e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—INS—metabolic syndrome X	1.38e-06	9.55e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—metabolic syndrome X	1.27e-06	8.75e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—metabolic syndrome X	1.23e-06	8.47e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NOS3—metabolic syndrome X	1.21e-06	8.37e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—metabolic syndrome X	1.2e-06	8.28e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—metabolic syndrome X	1.11e-06	7.66e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—metabolic syndrome X	1.04e-06	7.17e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—metabolic syndrome X	9.28e-07	6.4e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—metabolic syndrome X	9.06e-07	6.25e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—metabolic syndrome X	8.53e-07	5.89e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—metabolic syndrome X	8.46e-07	5.84e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—metabolic syndrome X	7.23e-07	4.99e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—metabolic syndrome X	5.58e-07	3.85e-06	CbGpPWpGaD
